<DOC>
	<DOCNO>NCT02759575</DOCNO>
	<brief_summary>The purpose research study test safety benefit add pembrolizumab ( therapy activate immune system fight cancer ) standard care treatment cancer . The standard care treatment include chemotherapy radiation 7 week .</brief_summary>
	<brief_title>A Study Chemoradiation Plus Pembrolizumab Locally Advanced Laryngeal Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Biopsyproven , previously untreated stage III IV squamous cell carcinoma larynx , Primary tumor stage ( T2 , T3 ) nodal stage ( N0 , N1 , N2 , N3 ) . Measurable disease base RECIST 1.1 . Performance status 0 1 Eastern Cooperative Oncology Group Performance Scale . Anticipated survival minimum 12 month . Adequate labs Patients T1 primary tumor T4 large volume tumor result larynx dysfunction baseline ( example tumor largely penetrate base tongue result inability swallow baseline ) Prior radiation therapy larynx area involve neck . Distant metastasis Known history active tuberculosis ( TB ) , autoimmune disease , pneumonitis , infection , HIV , Hepatitis B , Hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>